We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Ovid Therapeutics Inc. (OVID) USD0.001

Sell:$2.15 Buy:$2.17 Change: $0.04 (1.89%)
Market closed |  Prices as at close on 17 May 2022 | Switch to live prices |
Change: $0.04 (1.89%)
Market closed |  Prices as at close on 17 May 2022 | Switch to live prices |
Change: $0.04 (1.89%)
Market closed |  Prices as at close on 17 May 2022 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Ovid Therapeutics Inc. is a biopharmaceutical company. The Company is focused on developing medicines for patients and families living with epilepsies, seizure-related disorders and neurological disorders. The Company’s programs include OV329 (GABA aminotransferase inhibitor), OV350, OV882, and OV815 and OV825. OV329 (GABA aminotransferase inhibitor) is a next-generation GABA aminotransferase inhibitor being developed for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms. OV329 functions by substantially reducing the activity of GABA aminotransferase (GABA-AT), a key enzyme responsible for the degradation of the brain’s major inhibitory neurotransmitter, GABA. OV350 is a small molecule that directly activates the KCC2 transporter, which is an important channel in seizure control. OV882, which is a short hairpin RNA (shRNA-551) for Angelman syndrome. OV815, which is a genetic therapy approach for KIF1A-associated neurological disorders.

Contact details

1460 Broadway Ste 15044
United States
+1 (646) 6617661

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$154.21 million
Shares in issue:
70.42 million
United States
US dollar
NASDAQ Comb. Composite

Key personnel

  • Jeremy Levin
    Chairman of the Board, President, Chief Executive Officer
  • Jeffrey Rona
    Chief Business and Financial Officer
  • Thomas Perone
    Chief Compliance Officer, General Counsel, Corporate Secretary
  • Jason Tardio
    Chief Commercial Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.